Precipio (PRPO) COO Sabet bought 19 shares for $531 at $27.93
Insider transactions reported
Ahmed Zaki Sabet (Chief Operating Officer at Precipio Inc., PRPO) reported that they bought 19 shares for $531 at $27.93 on Apr 1, 2026. After these transactions the filing shows 1,034 shares held directly.
- Reporting person
- Sabet Ahmed Zaki
- Role
- Chief Operating Officer
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Apr 1, 2026 | Open-market purchase (P) | Common Stock1 | +19 | $27.93 | $531 | 1,034 direct |
Holdings before and after
- Common Stock: 1,015 to 1,034 direct
Footnotes from the filing
- 1. These shares are being purchased pursuant to 10b5-1 plan adopted by the Reporting Person.
Transaction codes in this filing
- Open-market purchase:
- Code P marks a purchase in the open market or a private deal. The insider paid for these securities.
FAQ
What did Sabet report in this PRPO Form 4?
Ahmed Zaki Sabet (Chief Operating Officer at Precipio Inc., PRPO) reported that they bought 19 shares for $531 at $27.93 on Apr 1, 2026. After these transactions the filing shows 1,034 shares held directly.
How many PRPO shares does Sabet hold after this filing?
The filing shows 1,034 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
What does transaction code P mean on an SEC Form 4?
Code P marks a purchase in the open market or a private deal. The insider paid for these securities.
Historical context for PRPO
Across the 8 sessions after earlier PRPO headlines, the stock closed higher 3 times and lower 4 times, with a median move of 3.2% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | PRPO | SPY |
|---|---|---|---|
| Mar 13, 2026 | Precipio Announces Q4 and year-end 2025 Shareholder Update Call | -6.7% | -0.6% |
| Mar 10, 2026 | Precipio Announces Publication of a Joint Study with Memorial Sloan-Kettering Cancer Center Highlighting Its Cutting-Edge Bloodhound BCR::ABL1 Assay | +3.3% | -0.2% |
| Feb 25, 2026 | Precipio 2025 (Unaudited) Revenues Grew to $24.0M, a 30% Increase Year-Over-Year | -3.9% | +0.8% |
| Jan 15, 2026 | Precipio Takes Major Steps Toward a Clean Balance Sheet | +0.0% | +0.3% |
| Dec 5, 2025 | Precipio to Showcase its BCR::ABL1 panel at 2025 ASH (American Society of Hematology) Meeting | -2.4% | +0.2% |
| Dec 4, 2025 | Precipio Identifies Unauthorized Access to Isolated Storage; No Operational Impact | -3.1% | +0.1% |
Earlier insider filings at PRPO
- Jan 20, 2026Amendment: Director Andrews Ronald Asbury was granted 568 shares, increasing direct ownership by 4% to 15,796 units (SEC Form 4)
- Jan 20, 2026Amendment: Director Cohen David Seth was granted 746 shares, increasing direct ownership by 1% to 53,688 units (SEC Form 4)
- Jan 20, 2026Amendment: Director Cossman Jeffrey was granted 597 shares, increasing direct ownership by 4% to 15,340 units (SEC Form 4)
- Jan 20, 2026Amendment: Chief Operating Officer Sabet Ahmed Zaki bought $468 worth of shares (20 units at $23.40), increasing direct ownership by 2% to 1,015 units (SEC Form 4)
- Jan 20, 2026Amendment: Chief Operating Officer Sabet Ahmed Zaki bought $488 worth of shares (25 units at $19.50), increasing direct ownership by 3% to 995 units (SEC Form 4)
- Market cap
- 30-day
- Sector
- Industrials
- Industry
- Biotechnology: Laboratory Analytical Instruments
Follow PRPO and get a push notification the moment its next story breaks.